Odactra, a sublingual immunotherapy tablet, aims to desensitize individuals to house dust mite allergens. The timeframe for experiencing noticeable improvements varies among individuals, but a typical treatment course involves daily administration for several months. This duration is necessary for the immune system to gradually adapt and reduce allergic reactions.
The effectiveness of allergen immunotherapy, including Odactra, hinges on consistent and prolonged exposure to the allergen. This sustained exposure allows the body to build tolerance, mitigating symptoms such as rhinitis, conjunctivitis, and asthma triggered by dust mites. Historically, allergy desensitization has relied on injection-based methods, requiring frequent clinic visits. Sublingual tablets offer a more convenient administration route, potentially improving adherence to the prescribed treatment schedule.
